Replimune to resubmit melanoma drug application after FDA feedback

Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read

Key Changes

• high

  Company will resubmit BLA for RP1 plus nivolumab in advanced melanoma following collaborative FDA communications, indicating the original application was not approved but the agency has provided a path forward.

  Item 8.01 view on EDGAR →
• high

  The resubmission represents a delay in potential product approval for the company's lead combination therapy, though FDA guidance suggests regulatory concerns may be addressable.

  8-K: BLA Update verify on EDGAR →